Lv11
60 积分 2021-08-27 加入
New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024
1小时前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
1小时前
已完结
NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity
5天前
已完结
Characterization of FGF21 Sites of Production and Signaling in Mice
24天前
已完结
Computational Analysis of B‐Cell Receptor (BCR) Immune Repertoires with Abalign
1个月前
已完结
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition
2个月前
已完结
Hepatic fibroblast growth factor 21 overexpression attenuates diet-induced hepatic steatosis and inflammation
5个月前
已完结
Hepatokines and Their Role in Cardiohepatic Interactions in Heart Failure
5个月前
已完结
Current status and future trends of the global burden of MASLD
8个月前
已完结
Analytical Comparison of the Originator Granulocyte-colony Stimulating Factor Filgrastim and its Biosimilars
9个月前
已完结
皖公网安备34019202002308
